- Conditions
- Apoptotic DNA Damage, Rheumatoid Arthritis, T-cell Lymphocytosis
- Interventions
- Group 1 or Orencia treated group, Group 2 (DMARDS treated group)
- Drug · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced May 21, 2026, 8:13 PM EDT